Global Gaucher Disease treatment market to reach $1.16 bn by 2024

Market dominance of the US is set to continue during the forecast period, with the country commanding approximately 56.2% of the Gaucher disease treatment space in the 7MM by 2024


(Photo Courtesy:

Sales of Gaucher disease therapeutics will rise gradually from $875 million in 2014 to $1.16 billion by 2024 across the seven major markets (7MM) of the UK, Italy, Spain, France, Germany, the US and Israel, at a Compound Annual Growth Rate (CAGR) of 2.9%, according to research and consulting firm GlobalData.

The company's latest report states that while a lack of drugs in late-stage development will limit the expansion of the Gaucher disease treatment market by 2024, growth will be driven by an increase in the number of diagnosed prevalent Gaucher disease cases, meaning the treated population is rising.

Dr Edit Kovalcsik, GlobalData's Analyst covering Cardiovascular and Metabolic Disorders, comments: "This increase can be attributed to continued efforts by Genzyme and Shire to raise awareness of such a rare condition as Gaucher disease.

"It can also be credited to new screening programs, such as the lysosomal storage disorder new-born screening program introduced in the state of Missouri."

The analyst adds that despite the anticipated improvements in diagnosis and treatment, a large portion of the Gaucher disease population will go untreated over the forecast period, due to continued late diagnosis and misdiagnosis of Gaucher disease as a result of its heterogeneous manifestations.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email